加州大学欧文分校，加州干细胞合作伙伴创建可移植 3D 视网膜

jack1381818

- }8 O; a4 z4 Z
2014 年 2 月 11 日$ W! e9 C9 L7 g/ S+ S
CSC干细胞发展公司最近宣布大授予已启用它努力开发可移植的 3D 视网膜与加利福尼亚大学欧文分校的合伙人。5 w# H8 x0 ]' q& d+ d& p* U6 L
- {) q  i: E, T/ a$ w) b4 [; ]& b

5 V7 l* p$ u8 I! E加州干细胞 (CSC) 和加利福尼亚大学，欧文分校 (UCI) 被授予 $450 万补助金从加州研究所的再生医学研究中，这是 CSC 研究的延续，一篇新闻稿。; [' {* e1 i) w, g# M' k
, _) t& p  z8 i7 I  S
作为详细的 CSC，该公司将利用其生产设施和人员区分和培养干细胞。在体内外研究然后将在 UCI 的苏 & 比尔格罗斯干细胞研究中心举行。. M; f+ C+ Z8 o0 L& j$ q' ?: f

- k. @8 V! @) O: H# F7 a# I"这项研究建立了一个非常有才华的科学家在一所大学在研究中，其卓越而闻名的团队和我们之间宝贵的伙伴关系"汉斯 · 基尔斯特德，博士，CSC 主席兼首席执行官，在新闻稿中说。"加州干细胞期望作出有意义的贡献工作具有的潜力，帮助数以百万计从改变生活视网膜疾病的痛苦。
9 O1 c! A, f5 m7 ~1 h* y4 M6 W: U6 h; h0 W. h) x) e
如果成功，研究可能的治疗视网膜色素变性和年龄相关性黄斑变性，新闻中说。6 W6 e9 n( \9 W" u3 \1 ^

/ [5 b) A# r. G& W# Y7 J" ^* B0 zHealio (free registration)/Primary Care Optometry News (2/11)

hallok

  E! ]- x$ D9 u7 D" G* G  J; G+ c+ A2 h. T
感觉是翻译机翻译的
4 M' R% w% C8 ?" u原文是这个吗？
, x/ H. g; k% u+ u( Z/ `- w% f8 o" q5 b6 K; S! J1 v4 J
California Stem Cell Partners on CIRM Grant to Develop Transplantable 3D Retinas February 06, 2014 09:00 AM Eastern Standard Time
- K% E9 A) Y* i# Y( q' O: F# [
1 H+ B  Z" Z7 @; a7 `, F$ PIRVINE, Calif.--(BUSINESS WIRE)--California Stem Cell, Inc. (“CSC”) announced today the initiation of a collaborative study with the University of California, Irvine (UCI) aimed to create transplantable 3D retinal tissue. The study, funded by a $4.5 million grant from the California Institute of Regenerative Medicine (CIRM), is a continuation of methods pioneered by CSC scientists in 2010, and will investigate the potential of improving a patient’s visual function by transplanting human stem cell-derived three-dimensional (3D) retinal tissue into their retina. " A1 W. X" Q0 T( G6 `
, |8 x/ x4 b" G+ j
“This study establishes a valuable partnership between ourselves and a team of very talented scientists at a university known for its excellence in research”
+ C  d+ P& a4 V; U% n+ uCalifornia Stem Cell, using its specialized cGMP manufacturing facility and regulatory personnel, will differentiate human stem cells into retinal progenitor cells. These cells will then be co-cultured with stem cell-derived retinal pigment epithelium to create a 3D tissue structure suitable for transplantation. Proof of concept in-vivo studies will take place at UCI’s Sue & Bill Gross Stem Cell Research Center. Transplants are expected to develop into mature retina, interact with the host tissue, and subsequently improve the vision of retinal degenerative recipients. The study, if successful, could lead to new treatments for incurable retinal diseases such as retinitis pigmentosa and age-related macular degeneration, leading causes of vision loss for people age 50 and older1.
& q5 a& z: y2 K. k0 N3 L: c+ u# @% [7 H6 E; u" l! t6 D
CSC President & CEO Hans Keirstead, Ph.D. will lead the study’s work at CSC. “This study establishes a valuable partnership between ourselves and a team of very talented scientists at a university known for its excellence in research,” said Keirstead. “California Stem Cell looks forward to making a meaningful contribution to work that has the potential to help millions suffering from life-altering retinal diseases.” , L# n' L6 @6 u4 a
2 t4 P# Y2 Q! H+ M
The project adds to CSC’s pipeline of programs, which also includes two additional human stem cell-based preclinical therapeutic programs for motor neuron disease. - H) C' z* W# B/ k: G) H1 N# n
* {$ k( K1 E" ]- {  T
About California Stem Cell 7 _' b2 D3 i- H$ Q0 q
3 \: ~8 J: Z: R- ]! K$ N: p
California Stem Cell Inc. (CSC) is an Irvine, CA-based company focused on the development of stem cell-based therapies for metastatic cancers and neurological disorders.
( R2 s, k2 S! D' I. C+ e# h) X/ d% V9 F( D3 V- M/ C, b
CSC has proprietary methods to generate human stem cell lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and cGMP processes.
/ p2 a6 j6 p9 L2 ~4 G3 c+ S
2 l  b' J7 i( ~

incosc

! T9 Y7 j+ R1 |
是用软件翻译的吗？哈哈哈哈。。